We have located links that may give you full text access.
Voxel-based whole-lesion enhancement parameters: a study of its clinical value in differentiating clear cell renal cell carcinoma from renal oncocytoma.
Abdominal Radiology 2017 Februrary
PURPOSE: The purpose of this study was to compare whole-lesion (WL) enhancement parameters to single region of interest (ROI)-based enhancement in discriminating clear cell renal cell carcinoma (ccRCC) from renal oncocytoma.
MATERIALS AND METHODS: In this IRB-approved retrospective study, the surgical database was queried to derive a cohort of 94 postnephrectomy patients with ccRCC or oncocytoma (68 ccRCC, 26 oncocytoma), who underwent preoperative multiphase contrast-enhanced computed tomography (CECT) between June 2009 and August 2013. CT acquisitions were transferred to a three-dimensional workstation, and WL ROIs were manually segmented. WL enhancement and histogram distribution parameters skewness, kurtosis, standard deviation (SD), and interquartile range (IQR) were calculated. WL enhancement parameters were compared to single ROI-based enhancement using receiver operating characteristic (ROC) analysis.
RESULTS: Oncocytoma had significantly higher WL enhancement than ccRCC in nephrographic (mean, p = 0.02; median, p = 0.03) and excretory phases (mean, p = 0.03; median p < 0.01). ccRCC had significantly higher kurtosis than oncocytoma in corticomedullary (p = 0.03) and excretory phases (p < 0.01), and significantly higher SD and IQR than oncocytoma in all postcontrast phases: corticomedullary (SD, p = 0.02; IQR, p < 0.01), nephrographic (SD, p = 0.01; IQR, p = 0.03), and excretory (SD, p < 0.01; IQR, p < 0.01). When compared to single ROI-based enhancement, WL enhancement alone did not demonstrate a statistical advantage in discriminating between ccRCC and oncocytoma (area under ROC curve of 0.78 and 0.72 respectively), but when combined with histogram distribution parameters (area under ROC curve of 0.86), it did demonstrate a slight improvement.
CONCLUSION: Our study suggests that voxel-based WL enhancement parameters provide only a slight improvement over single ROI-based enhancement techniques in differentiating between ccRCC and renal oncocytoma.
MATERIALS AND METHODS: In this IRB-approved retrospective study, the surgical database was queried to derive a cohort of 94 postnephrectomy patients with ccRCC or oncocytoma (68 ccRCC, 26 oncocytoma), who underwent preoperative multiphase contrast-enhanced computed tomography (CECT) between June 2009 and August 2013. CT acquisitions were transferred to a three-dimensional workstation, and WL ROIs were manually segmented. WL enhancement and histogram distribution parameters skewness, kurtosis, standard deviation (SD), and interquartile range (IQR) were calculated. WL enhancement parameters were compared to single ROI-based enhancement using receiver operating characteristic (ROC) analysis.
RESULTS: Oncocytoma had significantly higher WL enhancement than ccRCC in nephrographic (mean, p = 0.02; median, p = 0.03) and excretory phases (mean, p = 0.03; median p < 0.01). ccRCC had significantly higher kurtosis than oncocytoma in corticomedullary (p = 0.03) and excretory phases (p < 0.01), and significantly higher SD and IQR than oncocytoma in all postcontrast phases: corticomedullary (SD, p = 0.02; IQR, p < 0.01), nephrographic (SD, p = 0.01; IQR, p = 0.03), and excretory (SD, p < 0.01; IQR, p < 0.01). When compared to single ROI-based enhancement, WL enhancement alone did not demonstrate a statistical advantage in discriminating between ccRCC and oncocytoma (area under ROC curve of 0.78 and 0.72 respectively), but when combined with histogram distribution parameters (area under ROC curve of 0.86), it did demonstrate a slight improvement.
CONCLUSION: Our study suggests that voxel-based WL enhancement parameters provide only a slight improvement over single ROI-based enhancement techniques in differentiating between ccRCC and renal oncocytoma.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app